Geode Capital Management
ANIK icon

Geode Capital Management’s Anika Therapeutics ANIK Stock Holding History

Geode Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.85M Buy
331,577
+1,526
+0.5% +$22.6K ﹤0.01% 2937
2026
Q1 		$4.79M Buy
330,051
+4,529
+1% +$52.6K ﹤0.01% 2761
2025
Q4 		$3.13M Sell
325,522
-10,159
-3% -$97.3K ﹤0.01% 2987
2025
Q3 		$3.16M Buy
335,681
+14,470
+5% +$138K ﹤0.01% 3009
2025
Q2 		$3.4M Sell
321,211
-8,787
-3% -$111K ﹤0.01% 2928
2025
Q1 		$4.96M Buy
329,998
+7,220
+2% +$120K ﹤0.01% 2659
2024
Q4 		$5.31M Sell
322,778
-2,186
-0.7% -$43.1K ﹤0.01% 2721
2024
Q3 		$8.03M Sell
324,964
-16,104
-5% -$418K ﹤0.01% 2497
2024
Q2 		$8.64M Buy
341,068
+11,905
+4% +$309K ﹤0.01% 2413
2024
Q1 		$8.36M Buy
329,163
+10,250
+3% +$248K ﹤0.01% 2432
2023
Q4 		$7.23M Buy
318,913
+13,053
+4% +$270K ﹤0.01% 2507
2023
Q3 		$5.7M Buy
305,860
+10,978
+4% +$228K ﹤0.01% 2576
2023
Q2 		$7.66M Buy
294,882
+10,217
+4% +$273K ﹤0.01% 2455
2023
Q1 		$8.18M Buy
284,665
+9,043
+3% +$269K ﹤0.01% 2382
2022
Q4 		$8.16M Buy
275,622
+11,421
+4% +$325K ﹤0.01% 2390
2022
Q3 		$6.29M Buy
264,201
+2,879
+1% +$66.3K ﹤0.01% 2548
2022
Q2 		$5.83M Buy
261,322
+7,742
+3% +$173K ﹤0.01% 2618
2022
Q1 		$6.37M Sell
253,580
-5,813
-2% -$177K ﹤0.01% 2649
2021
Q4 		$9.29M Buy
259,393
+730
+0.3% +$29.2K ﹤0.01% 2488
2021
Q3 		$11M Buy
258,663
+3,613
+1% +$149K ﹤0.01% 2389
2021
Q2 		$11M Buy
255,050
+12,637
+5% +$538K ﹤0.01% 2391
2021
Q1 		$9.89M Buy
242,413
+29,412
+14% +$1.12M ﹤0.01% 2380
2020
Q4 		$9.64M Buy
213,001
+3,889
+2% +$148K ﹤0.01% 2207
2020
Q3 		$7.4M Sell
209,112
-23,017
-10% -$831K ﹤0.01% 2153
2020
Q2 		$8.76M Buy
232,129
+18,362
+9% +$605K ﹤0.01% 2003
2020
Q1 		$6.18M Sell
213,767
-9,087
-4% -$368K ﹤0.01% 2014
2019
Q4 		$11.6M Buy
222,854
+2,332
+1% +$135K ﹤0.01% 1912
2019
Q3 		$12.1M Buy
220,522
+1,836
+0.8% +$94.3K ﹤0.01% 1811
2019
Q2 		$8.88M Buy
218,686
+21,032
+11% +$767K ﹤0.01% 2037
2019
Q1 		$5.98M Buy
197,654
+19,420
+11% +$665K ﹤0.01% 2225
2018
Q4 		$5.99M Buy
178,234
+6,329
+4% +$228K ﹤0.01% 2105
2018
Q3 		$7.25M Buy
171,905
+4,391
+3% +$174K ﹤0.01% 2137
2018
Q2 		$5.36M Buy
167,514
+28,036
+20% +$1.15M ﹤0.01% 2282
2018
Q1 		$6.93M Buy
139,478
+3,010
+2% +$170K ﹤0.01% 2030
2017
Q4 		$7.36M Buy
136,468
+3,906
+3% +$216K ﹤0.01% 1962
2017
Q3 		$7.69M Buy
132,562
+7,649
+6% +$400K ﹤0.01% 1921
2017
Q2 		$6.16M Buy
124,913
+7,877
+7% +$363K ﹤0.01% 2013
2017
Q1 		$5.08M Sell
117,036
-3,128
-3% -$149K ﹤0.01% 2098
2016
Q4 		$5.88M Sell
120,164
-3,454
-3% -$160K ﹤0.01% 1958
2016
Q3 		$5.91M Buy
123,618
+11,774
+11% +$582K ﹤0.01% 1855
2016
Q2 		$6M Buy
111,844
+3,225
+3% +$152K ﹤0.01% 1790
2016
Q1 		$4.86K Buy
108,619
+13,126
+14% +$532K ﹤0.01% 1890
2015
Q4 		$3.64M Buy
95,493
+1,773
+2% +$67.8K ﹤0.01% 2098
2015
Q3 		$2.98M Buy
93,720
+810
+0.9% +$28.2K ﹤0.01% 2172
2015
Q2 		$3.07M Buy
92,910
+6,077
+7% +$217K ﹤0.01% 2234
2015
Q1 		$3.57M Buy
86,833
+12,218
+16% +$494K ﹤0.01% 2058
2014
Q4 		$3.04M Sell
74,615
-9,051
-11% -$354K ﹤0.01% 2144
2014
Q3 		$3.07M Buy
83,666
+943
+1% +$40.7K ﹤0.01% 2096
2014
Q2 		$3.83M Buy
82,723
+9,116
+12% +$405K ﹤0.01% 1953
2014
Q1 		$3.02M Sell
73,607
-35,829
-33% -$1.33M ﹤0.01% 2090
2013
Q4 		$4.18M Buy
109,436
+55,132
+102% +$1.7M ﹤0.01% 1836
2013
Q3 		$1.3M Buy
54,304
+2,782
+5% +$62.4K ﹤0.01% 2450
2013
Q2 		$876K Buy
+51,522
New +$743K ﹤0.01% 2542

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management's ANIK Position: Q2 2026 in Review

Geode Capital Management increased its Anika Therapeutics (ANIK) stake by 0.46% in Q2 2026, buying an estimated $22.6K and bringing the position to 331,577 shares worth $4.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2937.

Geode Capital Management first reported a position in ANIK in Q2 2013 and has held it in 53 quarters since. The position peaked at $12.1M in Q3 2019. 123 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Geode Capital Management held 331,577 shares of Anika Therapeutics worth $4.85M as of Q2 2026.
  • Geode Capital Management bought 1,526 Anika Therapeutics shares in Q2 2026, an estimated $22.6K.
  • Anika Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2937 holding.
  • Geode Capital Management first reported a position in Anika Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Geode Capital Management's Anika Therapeutics position peaked at $12.1M in Q3 2019.
  • 123 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.